Every material Form 8-K Prestige Consumer Healthcare filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Prestige Consumer Healthcare reported fiscal second-quarter 2027 revenue of $336.3 million, up 22.7% from a year earlier, with adjusted diluted EPS of $1.13 versus $1.07. The company lowered its fiscal 2027 revenue and adjusted EPS guidance, citing variable Clear Eyes production at its Pillar5 facility, which is expected to reduce product availability and revenue in the second half.
Q2 reported revenue $336.3 million, up 22.7%; organic revenue fell 1.6% excluding acquisitions and foreign currency
Q2 GAAP diluted EPS $0.53 versus $0.86 a year earlier; adjusted diluted EPS $1.13 versus $1.07
Fiscal 2027 revenue outlook lowered to $1,280 million to $1,290 million from $1,290 million to $1,315 million
Fiscal 2027 adjusted diluted EPS outlook lowered to $4.48 to $4.55 from $4.55 to $4.65
On August 10, 2026, Senior Vice President, Operations Jeffrey Zerillo notified Prestige Consumer Healthcare Inc. that he will retire from that role and all other positions he holds with the company, effective August 14, 2026. The filing does not name a successor or describe any separation or compensation terms, so shareholders have limited information on how the operations role will be filled.
Retirement notice given August 10, 2026
Retirement effective August 14, 2026, covering the SVP Operations role and all other positions held
Filing signed by Christine Sacco, Chief Financial Officer and Chief Operating Officer
No successor or separation terms disclosed in the filing
Prestige Consumer Healthcare reported fiscal first-quarter 2027 revenue of $265.7 million, up 6.5%, with organic growth of 3.2%. GAAP diluted EPS fell to $0.61 from $0.95, while adjusted diluted EPS rose to $0.98 from $0.95 after excluding acquisition costs and Pillar5 facility remediation costs. The company raised its fiscal 2027 revenue and EPS outlook, which it said reflects only the addition of the Breathe Right and LaCorium acquisitions.
Q1 revenue $265.7 million, up 6.5% from $249.5 million; organic revenue growth 3.2%
GAAP net income $29.2 million, or $0.61 per diluted share, versus $47.5 million, or $0.95, a year earlier
Adjusted diluted EPS $0.98 versus $0.95; adjustments include $12.8 million of acquisition costs and $7.1 million of Pillar5 remediation costs
Fiscal 2027 revenue outlook raised to $1,290 to $1,315 million from $1,100 to $1,121 million; adjusted diluted EPS outlook raised to $4.55 to $4.65 from $4.42 to $4.51
Prestige Brands, a wholly owned subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due July 15, 2034, under an indenture dated July 15, 2026. The notes are unsecured and guaranteed by the parent company, adding $400 million of long-term debt that shareholders will carry alongside existing obligations.
Principal amount: $400.0 million of 6.250% senior notes due July 15, 2034
Interest payable January 15 and July 15 each year, starting January 15, 2027
Parent company and certain domestic subsidiaries guarantee the notes on an unsecured senior basis
Change of Control triggers an offer to repurchase at 101% of principal; notes may be redeemed from July 15, 2029
Prestige Consumer Healthcare completed its acquisition of LaCorium Health on July 1, 2026, for approximately $150 million in cash, and priced a $400 million offering of 6.25% senior notes due 2034. The company plans to use the notes proceeds, with cash on hand, to redeem its $400 million of 5.125% senior notes due 2028, which changes its interest expense. The filing reports no earnings figures, and the company will report first quarter fiscal 2027 results on August 6, 2026.
Acquisition of LaCorium Health closed July 1, 2026, for approximately $150 million in cash, financed with cash on hand and existing credit facilities
Borrower drew $95.0 million of additional term loans under a July 1, 2026 amendment to its credit agreement
$400 million of 6.25% senior notes due 2034 priced, with closing expected on or about July 15, 2026, to redeem the 5.125% notes due 2028
LaCorium generates approximately $40 million in annual revenue and is expected to generate approximately $12 million in EBITDA once integrated
Prestige Consumer Healthcare completed its $1.045 billion cash purchase of the Breathe Right brand and certain other brands on June 12, 2026, funded by a new term loan and cash on hand. The company also amended its asset-based revolving credit line, raising commitments to $225 million and extending its maturity five years from the closing date, and the filing describes Breathe Right as becoming Prestige's largest brand.
Purchase price of $1.045 billion in cash for Breathe Right and certain other brands from Foundation Consumer Brands, LLC, closed June 12, 2026
New term loan of $1.045 billion priced at Term SOFR plus 2.00%, with quarterly amortization of 0.25% and a possible second draw of up to $95.0 million to help fund the LaCorium Acquisition
ABL revolving line commitments increased to $225 million, with maturity extended five years from the closing date
Prestige Consumer Healthcare agreed to acquire LaCorium Health, an Australian skin care business, for about $150 million in cash, subject to adjustments including indebtedness. The same day it reported fiscal 2026 results showing lower revenue and lower full-year diluted EPS, alongside fiscal 2027 outlook ranges for revenue and adjusted diluted EPS that are above fiscal 2026 levels.
Sale and Purchase Deed for about $150 million in cash; closing expected in the second quarter of fiscal 2027, and either party may terminate before October 1, 2026 for an uncured breach.
Q4 fiscal 2026 revenue was $281.6 million, down 5.0% from $296.5 million; Q4 diluted EPS was $1.13 versus $1.00.
Fiscal 2026 revenue was $1,088.7 million, down 4.3%; diluted EPS was $3.91 versus $4.29, and adjusted diluted EPS was $4.38 versus $4.52.
Fiscal 2027 outlook: revenue of $1,100 million to $1,121 million, adjusted diluted EPS of $4.42 to $4.51, and free cash flow of $250 million or more.
On March 19, 2026, Prestige Consumer Healthcare's subsidiary agreed to acquire Breathe Right and other over-the-counter brands from Foundation for $1.045 billion in cash. The company plans to fund the deal with cash on hand and a new term loan, and expects pro-forma bank-defined net leverage of about 4.0x at closing, with a return below 3.0x targeted in fiscal 2028. Closing is expected in the first half of fiscal 2027 and remains subject to closing conditions, including Hart-Scott-Rodino clearance.
Purchase price is $1.045 billion in cash, or about $900 million net of anticipated tax benefits valued at $150 million.
The acquired portfolio generated about $200 million of revenue and $95 million of EBITDA for the twelve months ended December 31, 2025, a price of about 11.0x EBITDA.
Expected pro-forma bank-defined net leverage is about 4.0x at close, with a target of below 3.0x in fiscal 2028.
Either party may terminate if the deal has not closed by July 20, 2026, subject to exceptions.
Prestige Consumer Healthcare reported fiscal third-quarter 2026 results for the quarter ended December 31, 2025, with revenue of $283.4 million, down 2.4% from a year earlier, and diluted EPS of $0.97 versus $1.22. The company narrowed its fiscal 2026 revenue outlook to approximately $1.1 billion, and its adjusted diluted EPS outlook to approximately $4.54, the low end of its prior range, while keeping free cash flow guidance at $245 million or more.
Q3 revenue of $283.4 million, down from $290.3 million; the company attributed the decline mainly to limited ability to supply demand for Clear Eyes.
Q3 diluted EPS of $0.97 versus $1.22; adjusted diluted EPS of $1.14 versus $1.22 in the prior-year quarter.
Fiscal 2026 revenue outlook narrowed to approximately $1,100 million from $1,100 million to $1,115 million; organic revenue decline now approximately 3.0%.
Repurchased approximately 0.8 million shares for $45.8 million in Q3; Pillar5 Pharma acquisition closed in December.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Prestige Consumer Healthcare filing is on SEC EDGAR ↗. 8-K briefs of other companies →